Sandoz Strikes $500m Deal For GSK Cephalosporins
Deal To Acquire Cephalosporins Business Reinforces Position In Antibiotics
Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.
You may also be interested in...
Sandoz and Astellas have struck a deal that will see the Novartis subsidiary acquire global rights to the Mycamine micafungin antifungal brand, bolstering Sandoz’s anti-infectives portfolio and hospital offering.
Sandoz CEO Richard Saynor and global head of anti-infectives Ian Ball have spoken out on the threat of antimicrobial resistance and the “increasing dysfunctionality” of the market framework for antibiotics.
To increase manufacturing capacity for finished dosage form penicillins, Sandoz is investing another €50m into its key antibiotics site in Kundl, Austria. But the company feels that fundamental reforms are needed from regulators to ensure the long-term sustainability of European-based antibiotic manufacturing and supply.